Louisiana Senate Bill SR79

Louisiana 2010 Regular Session

• Introduced: 5/17/10
• Passed: 5/17/10

Caption

Designates May, 2010, as the Amyotrophic Lateral Sclerosis Awareness Month.

Impact

The resolution aims to raise public awareness about ALS and acknowledges the profound effects the disease has on patients, families, and communities. By designating a specific month for awareness, it encourages discussion and recognition of the struggles faced by those diagnosed with ALS, as well as the ongoing research efforts to combat the disease. Particularly noted in the resolution is the elevated risk for military veterans, which underlines the need for heightened awareness and support for affected individuals and their families.

Summary

Senate Resolution 79 (SR79), authored by Senator Michot, designates May 2010 as Amyotrophic Lateral Sclerosis (ALS) Awareness Month in Louisiana. ALS, commonly known as Lou Gehrig's disease, is a fatal neurodegenerative condition characterized by the degeneration of motor neurons, leading to significant impairment in muscle function. The resolution highlights the symptoms associated with ALS, including muscle weakness, difficulty in swallowing, and breathing challenges, eventually leading to severe physical disability while the patient's mental faculties remain intact. Moreover, it emphasizes the short average survival rate of two to five years post-diagnosis for ALS patients.

Sentiment

Overall sentiment surrounding SR79 appears to be positive, as it promotes compassion and understanding for ALS patients. The designation of a specific month for awareness is generally welcomed, as it fosters community support and encourages legislative and health policy discussions. Healthcare advocates and organizations supporting ALS research stand to benefit from increased public attention and recognition brought about by this resolution.

Contention

While SR79 itself is a resolution rather than a bill with legislative power, its passage reflects a collective commitment to shedding light on the challenges posed by ALS. It faces minimal contention, as it primarily serves to acknowledge the plight of those affected by the disease rather than proposing any regulatory changes or contentious actions. However, the ongoing issues surrounding ALS research funding and veteran health rights may resurface in discussions as awareness increases.